The major factors for the growth of the nucleic acid amplification testing (NAAT) market includes the rising prevalence of infectious diseases, increasing demand for advanced diagnostic measures, and rising investment for the development of new biotechnological diagnostic techniques.
The nucleic acid amplification tests (NAAT) offer sensitive detection, particularly when detecting low-density parasitaemias. The market is expected to witness high growth owing to the rise in preference for NAAT over traditional diagnostic testings.
NAAT detects particular nucleic acid, virus, or bacteria which acts as a pathogen in blood, tissue, urine, etc. Furthermore, this technique is also used for screening blood donations to reduce the risk of transfusion-transmitted infections in the recipients. Also, there is a rising prevalence of various infectious diseases which is expected to boost the growth of the market over the forecast period.
Key Market Trends
Infectious Disease Segment by Application is Expected to Hold the Largest Market Share Over the Forecast Period
The major factor driving the growth of the segment is the rising prevalence of various infectious diseases across the globe. For instance, as per the WHO’s 2017 Global Tuberculosis Report, approximately 6.3 million new cases of tuberculosis (TB) were reported in 2016. The report also estimated that the new cases corresponded to 61% of the estimated incidence of 10.4 million TB cases.
The NAAT are generally specific and highly sensitive and can be used for all categories of microorganisms. The recent advances have led to the development of multiplex assays. In the multiplex assays, the single nucleic acid-based test can detect and differentiate between more than two causative microorganisms. Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.
North America is Expected to Hold a Large Market Share Over the Forecast Period
The United States is expected to be the largest nucleic acid amplification testing market owing to the presence of better healthcare infrastructure and the rising prevalence of infectious diseases. In Canada the Canadian Blood Services implemented NAAT and it is providing safer blood supply by detecting low levels of viral genetic material.
Furthermore, NAAT is becoming the standard of practice in the blood and plasma industry in the United States and around the world. On the other hand, WHO recommends that the use of NAATs be considered only for research purposes until more evidence is available on the public health impact of detecting and treating low density infections. Thus, considering all the above-mentioned factors the market is expected to witness high growth.
The market studied is a consolidated market owing to the presence of few major market players. Some of the market players are Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Grifols SA, Hoffmann-La Roche Ltd, Hologic, Inc., and Illumina, Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support